The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | BFAST: High dose alectinib for RET-positive NSCLC
Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the safety and efficacy results of high-dose alectinib treatment for patients with treatment naïve RET-positive non-small cell lung cancer in the Blood First Assay Screening Trial (BFAST). BFAST (NCT03178552) is an ongoing study of targeted treatment/immunotherapy in treatment-naïve NSCLC, determined by the genomic features of a participant’s cell-free DNA. The RET cohort underwent Phase I dose-escalation with alectinib at a higher dose than is used as standard. While the study demonstrated tolerability of high dose alectinib, low response rates led to premature closure of Phase I enrollment, and Phase II was not started. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
